PortalPublikationenAllogeneic hematopoietic stem-cell transplantation for patie...

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Standard

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. / Guièze, Romain; Eikema, Diderik-Jan; Koster, Linda; Schetelig, Johannes; Sengeloev, Henrik; Passweg, Jakob; Finke, Jürgen; Arat, Mutlu; Broers, Annoek E C; Stölzel, Friedrich; Byrne, Jenny; Castilla-Llorente, Cristina; Dreger, Peter; Eder, Matthias; Gedde-Dahl, Tobias; Kröger, Nicolaus; Ribera Santasusana, Josep Maria; Richardson, Deborah; Rambaldi, Alessandro; Yañez, Lucrecia; Van Gelder, Michel; Drozd-Sokolowska, Joanna; Raj, Kavita; Yakoub-Agha, Ibrahim; Tournilhac, Olivier; McLornan, Donal P.

in: BONE MARROW TRANSPL, Jahrgang 59, Nr. 7, 07.2024, S. 950-956.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Guièze, R, Eikema, D-J, Koster, L, Schetelig, J, Sengeloev, H, Passweg, J, Finke, J, Arat, M, Broers, AEC, Stölzel, F, Byrne, J, Castilla-Llorente, C, Dreger, P, Eder, M, Gedde-Dahl, T, Kröger, N, Ribera Santasusana, JM, Richardson, D, Rambaldi, A, Yañez, L, Van Gelder, M, Drozd-Sokolowska, J, Raj, K, Yakoub-Agha, I, Tournilhac, O & McLornan, DP 2024, 'Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT', BONE MARROW TRANSPL, Jg. 59, Nr. 7, S. 950-956. https://doi.org/10.1038/s41409-024-02256-9

APA

Guièze, R., Eikema, D-J., Koster, L., Schetelig, J., Sengeloev, H., Passweg, J., Finke, J., Arat, M., Broers, A. E. C., Stölzel, F., Byrne, J., Castilla-Llorente, C., Dreger, P., Eder, M., Gedde-Dahl, T., Kröger, N., Ribera Santasusana, J. M., Richardson, D., Rambaldi, A., ... McLornan, D. P. (2024). Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL, 59(7), 950-956. https://doi.org/10.1038/s41409-024-02256-9

Vancouver

Guièze R, Eikema D-J, Koster L, Schetelig J, Sengeloev H, Passweg J et al. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL. 2024 Jul;59(7):950-956. https://doi.org/10.1038/s41409-024-02256-9

Bibtex

@article{41ea38bed0f64f0c8793fbfd57add0ce,
title = "Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT",
abstract = "Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3-63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9-11) and 28 (42.4%) were in complete remission (CR). The majority underwent reduced intensity conditioning (66.2%) using peripheral blood derived stem cells. Eighteen (27.3%) patients had a matched sibling donor, 24 (36.4%) a matched unrelated donor and the remaining were mismatched. Median follow-up was 6.6 years; 1- and 3- year overall and progression free survival (PFS) (95% CI) was 65% (54-77) and 39% (27-51) and 53% (41-65) and 29% (18-40), respectively. Patients in CR at time of allo-HCT had significantly better 3-year PFS (39% vs. 21%, p = 0.032). Cumulative incidences of grade II-IV acute graft versus host disease (GVHD) at day +100 was 41% (95% CI 29-53) and chronic GVHD at 3 years was 53% (95% CI 41-65). High rates of non-relapse mortality (NRM) were observed; 38% (95% CI, 26-50) at 3 years. Although potentially curative, approaches to reduce considerable NRM and chronic GVHD rates are required.",
author = "Romain Gui{\`e}ze and Diderik-Jan Eikema and Linda Koster and Johannes Schetelig and Henrik Sengeloev and Jakob Passweg and J{\"u}rgen Finke and Mutlu Arat and Broers, {Annoek E C} and Friedrich St{\"o}lzel and Jenny Byrne and Cristina Castilla-Llorente and Peter Dreger and Matthias Eder and Tobias Gedde-Dahl and Nicolaus Kr{\"o}ger and {Ribera Santasusana}, {Josep Maria} and Deborah Richardson and Alessandro Rambaldi and Lucrecia Ya{\~n}ez and {Van Gelder}, Michel and Joanna Drozd-Sokolowska and Kavita Raj and Ibrahim Yakoub-Agha and Olivier Tournilhac and McLornan, {Donal P}",
note = "{\textcopyright} 2024. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2024",
month = jul,
doi = "10.1038/s41409-024-02256-9",
language = "English",
volume = "59",
pages = "950--956",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

AU - Guièze, Romain

AU - Eikema, Diderik-Jan

AU - Koster, Linda

AU - Schetelig, Johannes

AU - Sengeloev, Henrik

AU - Passweg, Jakob

AU - Finke, Jürgen

AU - Arat, Mutlu

AU - Broers, Annoek E C

AU - Stölzel, Friedrich

AU - Byrne, Jenny

AU - Castilla-Llorente, Cristina

AU - Dreger, Peter

AU - Eder, Matthias

AU - Gedde-Dahl, Tobias

AU - Kröger, Nicolaus

AU - Ribera Santasusana, Josep Maria

AU - Richardson, Deborah

AU - Rambaldi, Alessandro

AU - Yañez, Lucrecia

AU - Van Gelder, Michel

AU - Drozd-Sokolowska, Joanna

AU - Raj, Kavita

AU - Yakoub-Agha, Ibrahim

AU - Tournilhac, Olivier

AU - McLornan, Donal P

N1 - © 2024. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2024/7

Y1 - 2024/7

N2 - Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3-63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9-11) and 28 (42.4%) were in complete remission (CR). The majority underwent reduced intensity conditioning (66.2%) using peripheral blood derived stem cells. Eighteen (27.3%) patients had a matched sibling donor, 24 (36.4%) a matched unrelated donor and the remaining were mismatched. Median follow-up was 6.6 years; 1- and 3- year overall and progression free survival (PFS) (95% CI) was 65% (54-77) and 39% (27-51) and 53% (41-65) and 29% (18-40), respectively. Patients in CR at time of allo-HCT had significantly better 3-year PFS (39% vs. 21%, p = 0.032). Cumulative incidences of grade II-IV acute graft versus host disease (GVHD) at day +100 was 41% (95% CI 29-53) and chronic GVHD at 3 years was 53% (95% CI 41-65). High rates of non-relapse mortality (NRM) were observed; 38% (95% CI, 26-50) at 3 years. Although potentially curative, approaches to reduce considerable NRM and chronic GVHD rates are required.

AB - Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3-63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9-11) and 28 (42.4%) were in complete remission (CR). The majority underwent reduced intensity conditioning (66.2%) using peripheral blood derived stem cells. Eighteen (27.3%) patients had a matched sibling donor, 24 (36.4%) a matched unrelated donor and the remaining were mismatched. Median follow-up was 6.6 years; 1- and 3- year overall and progression free survival (PFS) (95% CI) was 65% (54-77) and 39% (27-51) and 53% (41-65) and 29% (18-40), respectively. Patients in CR at time of allo-HCT had significantly better 3-year PFS (39% vs. 21%, p = 0.032). Cumulative incidences of grade II-IV acute graft versus host disease (GVHD) at day +100 was 41% (95% CI 29-53) and chronic GVHD at 3 years was 53% (95% CI 41-65). High rates of non-relapse mortality (NRM) were observed; 38% (95% CI, 26-50) at 3 years. Although potentially curative, approaches to reduce considerable NRM and chronic GVHD rates are required.

U2 - 10.1038/s41409-024-02256-9

DO - 10.1038/s41409-024-02256-9

M3 - SCORING: Journal article

C2 - 38503942

VL - 59

SP - 950

EP - 956

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 7

ER -